Breast Cancer Liquid Biopsy

Global Market Trajectory & Analytics

MCP21384

EXECUTIVE ENGAGEMENTS

POOL

782
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

156
Interactions with Platform & by Email

PARTICIPANTS

31
Unique # Participated

VALIDATIONS

13
Responses Validated*

COMPANIES

34
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

108

PAGES

172

EDITION

5

PRICE

USD 5600

CODE

MCP21384


COMPETITIVE METRICS

COMPANY

D S N T

% *

*Login to Participate & View Data Stacks
View 34 Companies...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Breast Cancer Liquid Biopsy estimated at US$262.6 Million in the year 2020, is projected to reach a revised size of US$936.3 Million by 2027, growing at a CAGR of 19.9% over the analysis period 2020-2027. Cell-Free DNA (cfDNA), one of the segments analyzed in the report, is projected to record a 20.1% CAGR and reach US$387.8 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Circulating Tumor Cells (CTCs) segment is readjusted to a revised 22.3% CAGR for the next 7-year period.
The Breast Cancer Liquid Biopsy market in the U.S. is estimated at US$78.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$164.4 Million by the year 2027 trailing a CAGR of 19.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.9% and 16.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.
In the global Extracellular Vesicles (EVs) segment, USA, Canada, Japan, China and Europe will drive the 17.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$41.3 Million in the year 2020 will reach a projected size of US$127.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$109.2 Million by the year 2027.

SELECT PLAYERS

Biodesix, Inc.; Bio-Rad Laboratories; Cynvenio Biosystems, Inc.; Fluxion Biosciences, Inc.; Genomic Health, Inc.; Guardant Health, Inc.; Illumina; Isogen Life Science B.V.; Menarini Silicon Biosystems; Myriad Genetics

SEGMENTS

» Circulating Biomarker (Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs), Other Circulating Biomarkers) » End-Use (Reference Laboratories, Hospitals & Physician Laboratories, Other End-Uses)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Cell-Free DNA (cfDNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Cell-Free DNA (cfDNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cell-Free DNA (cfDNA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Circulating Tumor Cells (CTCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Circulating Tumor Cells (CTCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Circulating Tumor Cells (CTCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Extracellular Vesicles (EVs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Extracellular Vesicles (EVs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Extracellular Vesicles (EVs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Circulating Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Circulating Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Circulating Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hospitals & Physician Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hospitals & Physician Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospitals & Physician Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
China Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
France Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
Total Companies Profiled: 34

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com